[The difficult management of patients with type 2 diabetes and renal disease: from diagnosis to treatment]

Roberto Pontremoli, Francesca Cappadona, Anna Solini

DOI: https://doi.org/10.7175/cmi.v10i1.1224

Abstract

The prevalence of type 2 diabetes mellitus and arterial hypertension is on the rise in western countries and chronic kidney disease is certainly one of their most harmful complications. This condition greatly complicates patient management. The clinician needs to wisely identify the best diagnostic algorithm and carefully balance potential risks and benefits of each therapeutic decision.Even when recommended therapeutic targets can be achieved, often a challenging task in clinical practice, residual cardiovascular and renal risk remains unacceptably high for these patients.

Here we present the case of a 72-year old woman, with arterial hypertension and diabetes mellitus type 2. Despite the long clinical history of the patient, being treated for over 20 years,blood pressure and metabolic control were not satisfactory. The authors trace the patient’s treatment pathway, following the different clinical questions that led them to the modification of the patient’s therapy. The new therapy is based on chlorthalidone, sitagliptin, a combinationtherapy of ezetimibe / simvastatin, and metformin.

 

[Article in Italian]

Keywords

Hypertension; Diabetes; Cardiovascular risk; Renal disease

Full Text:

HTML PDF

References

  • Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.77
  • Viazzi F, Leoncini G, Derchi LE, et al. Ultrasound Doppler renal resistive index: a useful tool for the management of the hypertensive patient. J Hypertens 2014 Jan;32(1):149-53; http://dx.doi.org/10.1097/HJH.0b013e328365b29c
  • Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23: 3-16; http://dx.doi.org/10.3109 /08037051.2014.868629
  • Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9(4 Pt 1): 342-60
  • Cirillo M, Marcarelli F, Mele AA, et al. Parallel-group 8-week study on chlorthalidone effects in hypertensives with low kidney function. Hypertension 2014; 63: 692-7; http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.02793
  • Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312: 2668-75; http://dx.doi.org/ 10.1001/jama.2014.15298
  • Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 2014; 370: 1514-23; http://dx.doi.org/10.1056/NEJMoa1310799
  • Associazione Medici Diabetologi. La personalizzazione della terapia nel diabete di tipo 2. http://www.aemmedi.it/algoritmi_it_2014 [ultimo accesso marzo 2016]
  • Leoncini G, Viazzi F, Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep 2010; 12: 335-41; http://dx.doi.org/10.1007/s11906-010-0141-3

Refbacks

  • There are currently no refbacks.




© SEEd srl